The Integration of Cell Therapy and Biomaterials as Treatment Strategies for Remyelination.
Eneritz López-MuguruzaNatalia Villar-GómezJordi A Matias-GuiuBelen Selma-CalvoLidia Moreno-JimenezFrancisco Sancho-BielsaJuan Lopez-CarboneroMaría Soledad Benito-MartínSilvia García-FloresNatalia Bonel-GarcíaOla Mohamed-Fathy KamalDoddy Denise Ojeda-HernándezJorge Matias-GuiuUlises Gómez-PinedoPublished in: Life (Basel, Switzerland) (2022)
Multiple sclerosis (MS) is a chronic degenerative autoimmune disease of the central nervous system that causes inflammation, demyelinating lesions, and axonal damage and is associated with a high rate of early-onset disability. Disease-modifying therapies are used to mitigate the inflammatory process in MS but do not promote regeneration or remyelination; cell therapy may play an important role in these processes, modulating inflammation and promoting the repopulation of oligodendrocytes, which are responsible for myelin repair. The development of genetic engineering has led to the emergence of stable, biocompatible biomaterials that may promote a favorable environment for exogenous cells. This review summarizes the available evidence about the effects of transplantation of different types of stem cells reported in studies with several animal models of MS and clinical trials in human patients. We also address the advantages of combining cell therapy with biomaterials.
Keyphrases
- cell therapy
- multiple sclerosis
- stem cells
- early onset
- oxidative stress
- white matter
- mass spectrometry
- clinical trial
- induced apoptosis
- mesenchymal stem cells
- ms ms
- end stage renal disease
- late onset
- tissue engineering
- ejection fraction
- newly diagnosed
- endothelial cells
- bone regeneration
- chronic kidney disease
- signaling pathway
- cell cycle arrest
- gene expression
- prognostic factors
- genome wide
- copy number
- cerebrospinal fluid
- pluripotent stem cells
- cell death
- dna methylation
- optical coherence tomography
- case control